¡Ya estamos en ! Descubre más

Pacific Biosciences

PACB

Capitalización de mercado USD 538 M

1.73 USD

-0.23

11.73%

Al cierre Actualizado 16 oct, 4:00 p.m. EDT

Antes de la apertura del mercado

Después del cierre del mercado

1.73

0.00

0%

1 día

-11.73%

5 días

-22.77%

1 mes

29.1%

3 meses

16.11%

6 meses

6.13%

En lo que va del año

-5.98%

1 año

-1.7%

5 años

-92.88%

10 años

-79.65%

Acerca de: Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.

Empleados: 485

Atención médica Dispositivos médicos

Noticias

Positivo

Neutral

Negativo

Sentimiento 3 meses

Positivo 24.1%

Neutral 55.2%

Negativo 20.7%

Zacks Investment Research

Pacific Biosciences of California (PACB) Declines More Than Market: Some Information for Investors

In the most recent trading session, Pacific Biosciences of California (PACB) closed at $1.99, indicating a -2.93% shift from the previous trading day.

Pacific Biosciences of California (PACB) Declines More Than Market: Some Information for Investors

PacBio to Report Third Quarter 2026 Financial Results on November 4, 2026

MENLO PARK, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2026 financial results on Wednesday, November 4, 2026, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).

PacBio to Report Third Quarter 2026 Financial Results on November 4, 2026

Zacks Investment Research

PacBio Teams With TychoBio to Advance AI-Driven RNA Therapeutics

PACB partners with TychoBio to harness AI and long-read RNA sequencing for rare disease therapies, aiming to improve drug efficacy and safety through advanced data models.

PacBio Teams With TychoBio to Advance AI-Driven RNA Therapeutics

Zacks Investment Research

Why Pacific Biosciences of California (PACB) Dipped More Than Broader Market Today

The latest trading day saw Pacific Biosciences of California (PACB) settling at $2.3, representing a -15.44% change from its previous close.

Why Pacific Biosciences of California (PACB) Dipped More Than Broader Market Today

PacBio and TychoBio Collaborate to Train AI Models for Rare Disease RNA Therapeutics

PacBio Kinnex sequencing will generate full-length transcript data to help advance TychoBio's drug discovery models PacBio Kinnex sequencing will generate full-length transcript data to help advance TychoBio's drug discovery models

PacBio and TychoBio Collaborate to Train AI Models for Rare Disease RNA Therapeutics

Zacks Investment Research

Pacific Biosciences of California (PACB) Rises Higher Than Market: Key Facts

Pacific Biosciences of California (PACB) concluded the recent trading session at $2.54, signifying a +1.2% move from its prior day's close.

Pacific Biosciences of California (PACB) Rises Higher Than Market: Key Facts

Schaeffers Research

3 Biotech Stocks Put Traders Are Targeting Today

Nektar Therapeutics (NASDAQ:NKTR), Quantum-Si Inc (NASDAQ:QSI), and Pacific Biosciences of California Inc (NASDAQ:PACB) are all attracting elevated options activity today, as biotech stocks make volatile moves.

3 Biotech Stocks Put Traders Are Targeting Today

Zacks Investment Research

Pacific Biosciences of California (PACB) Beats Stock Market Upswing: What Investors Need to Know

In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.62, marking a +2.53% move from the previous day.

Pacific Biosciences of California (PACB) Beats Stock Market Upswing: What Investors Need to Know

Pacific Biosciences Targets Clinical Growth, $40M Savings With HiFi Sequencing Push

Pacific Biosciences of California NASDAQ: PACB is maintaining its existing strategy while sharpening execution around clinical genomics, cost controls and the rollout of products designed to improve sequencing economics, Chief Executive Officer Mark Van Oene said during a Morgan Stanley discussion.

Pacific Biosciences Targets Clinical Growth, $40M Savings With HiFi Sequencing Push

Zacks Investment Research

Why Pacific Biosciences of California (PACB) Outpaced the Stock Market Today

In the most recent trading session, Pacific Biosciences of California (PACB) closed at $1.38, indicating a +2.99% shift from the previous trading day.

Why Pacific Biosciences of California (PACB) Outpaced the Stock Market Today

Ver rankings de noticias

Gráficos de precios implementados con Lightweight Charts™